Prevention study enrolling women ages 25-55 with a BRCA1 mutation
This is a study to test the effectiveness of a drug (denosumab) on preventing the development of breast cancer in women with an inherited BRCA1 mutation.
Denosumab is a drug that is currently used to treat bone loss in order to reduce the risk of broken bones in healthy people, and is also used to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women with an inherited BRCA1 mutation.
This study will create a system to assess an individual’s risk of breast cancer
This study will create a system to assess an individual’s risk of breast cancer based on random sampling of normal breast tissue as well as determine new and help understand previously identified risk biomarkers.
Latinas with a high risk of breast cancer
This study will teach Latinas with a high risk of breast cancer about how diet, exercise, ethnicity, genetics and screening and prevention guidelines may impact their likelihood for developing breast cancer.
Study for people undergoing DIEP flap reconstruction
The goal of this study is to look at how well a nerve graft works for improving sensation to the reconstructed breast after mastectomy in people undergoing DIEP flap reconstruction (deep inferior epigastric perforator flap).
People with a BRCA1 or BRCA2 mutation
This study will look at a new vaccine known as INO-5401 used alone or combined with a second vaccine called INO-9012. The study will test if the vaccine is safe (without large side effects) and test a new way of giving vaccines. It will also test whether the vaccine activates the immune system. A goal of this research is to reduce cancer risk in people with a BRCA1 or BRCA2 mutation. Additional studies will be needed to learn if this vaccine approach lowers cancer risk in mutation carriers.
The Ohio State University and FORCE want to understand if a family communication guide for people with BRCA mutations is helpful and if it’s also useful to have a video that you can text or email to family members that explains your BRCA mutation. We are currently looking for people between the ages of 18-80 who have mutation in BRCA1 or BRCA2, have an active email address, and an internet capable device like a computer, tablet, or smartphone. Participants will be asked to complete a total of 3 surveys. Participants will be randomly assigned to either receive just the communication guide or the guide plus the sharable. Each survey will take 10-15 minutes (the study could take up to 1.5 hours to complete depending on how much time you spend reviewing the study materials).
You can get more information or ask to participate in the study by sending an email to: [email protected].
The purpose of this study is to see how cancer treatment affects the ovaries, such as the impact on conceiving a child or the early onset of menopause. Comparatively, the study will also look at high-risk women with BRCA1/2 mutations (and no evidence of breast or ovarian cancer).
The study will check blood levels of hormones that the ovaries produce and will use questionnaires to gather information about participant menstrual cycles, health, and pregnancies.
The purpose of this study is to evaluate if denosumab can reduce the breast density of premenopausal women who have dense breasts. Denosumab is an FDA-approved injectable medication that is used to treat osteoporosis and to prevent fractures in cancer patients with bone metastases. This study could help us identify novel ways to prevent breast cancer in younger women.
A new study is recruiting people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason.
This is a study of people with "secondary results” from genetic testing. Secondary results are unexpected. They are not related to the reason the person had the genetic test but are shared because they may be very important to the person’s health. Most secondary results have to do with high risks for health problems that can be treated or prevented. Many of these results are related to cancer risk. If you think you have received a secondary result, you may be eligible to join this study.
The goal of the Wisdom Study is to determine if breast cancer screening can be made better by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all, annual approach. The Wisdom Study is designed to end the confusion about when to start and how often to have a mammogram. For more information, visit the WISDOM Study website.
Additional Results on Clinicaltrials.gov Prevention, Detection & Risk + Breast Cancer
Developing and Evaluating Culturally Relevant Interventions to Improve Breast Cancer Screening
NCT ID: NCT05665660 (https://classic.clinicaltrials.gov/show/NCT05665660)
Promoting Informed Choice for Breast Cancer Screening: A Longitudinal Study
NCT ID: NCT05838417 (https://classic.clinicaltrials.gov/show/NCT05838417)
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
NCT ID: NCT05625659 (https://classic.clinicaltrials.gov/show/NCT05625659)
Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women
NCT ID: NCT05298605 (https://classic.clinicaltrials.gov/show/NCT05298605)
The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts
NCT ID: NCT05667532 (https://classic.clinicaltrials.gov/show/NCT05667532)
Early Detection of Breast Cancer
NCT ID: NCT06043661 (https://classic.clinicaltrials.gov/show/NCT06043661)
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
NCT ID: NCT04030507 (https://classic.clinicaltrials.gov/show/NCT04030507)
Novel Thermal Imaging Technique for Breast Screening
NCT ID: NCT05650086 (https://classic.clinicaltrials.gov/show/NCT05650086)
BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity
NCT ID: NCT05051631 (https://classic.clinicaltrials.gov/show/NCT05051631)
Droplet-BC Screening Test for the Detection of Breast Cancer, the DROPLET-BC Study
NCT ID: NCT04671498 (https://classic.clinicaltrials.gov/show/NCT04671498)
Empowering Latinas to Obtain Guideline Concordant Screenings
NCT ID: NCT05841355 (https://classic.clinicaltrials.gov/show/NCT05841355)
Interventional Program Educates, Identifies + Overcomes Barriers to Complete Screening Mammography
NCT ID: NCT04348123 (https://classic.clinicaltrials.gov/show/NCT04348123)
A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer
NCT ID: NCT05408260 (https://classic.clinicaltrials.gov/show/NCT05408260)
Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening
NCT ID: NCT04904757 (https://classic.clinicaltrials.gov/show/NCT04904757)
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
NCT ID: NCT03729115 (https://classic.clinicaltrials.gov/show/NCT03729115)
Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts
NCT ID: NCT04854304 (https://classic.clinicaltrials.gov/show/NCT04854304)
Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics
NCT ID: NCT05694559 (https://classic.clinicaltrials.gov/show/NCT05694559)
Searching for Masses and Calcifications at the Same Time in Breast Cancer Screening
NCT ID: NCT05975736 (https://classic.clinicaltrials.gov/show/NCT05975736)
Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania
NCT ID: NCT04085510 (https://classic.clinicaltrials.gov/show/NCT04085510)
Mammogram Mail- and Phone-based Interventions
NCT ID: NCT05853848 (https://classic.clinicaltrials.gov/show/NCT05853848)
Project 1: Self-Triage by 2D Full-field Digital Mammography or Synthetic Images
NCT ID: NCT05960188 (https://classic.clinicaltrials.gov/show/NCT05960188)
Improving Cancer Screening and Follow-up in Community Health Centers
NCT ID: NCT05756725 (https://classic.clinicaltrials.gov/show/NCT05756725)
Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care
NCT ID: NCT05483283 (https://classic.clinicaltrials.gov/show/NCT05483283)
Autoantibodies in Breast Cancer Detection
NCT ID: NCT03623945 (https://classic.clinicaltrials.gov/show/NCT03623945)
Southeast Asian Women's Health Project
NCT ID: NCT04086771 (https://classic.clinicaltrials.gov/show/NCT04086771)
UCLA Breast Cancer Survivor Health Promotion Research Study
NCT ID: NCT05113485 (https://classic.clinicaltrials.gov/show/NCT05113485)
Protocol for Women at Increased Risk of Developing Breast Cancer
NCT ID: NCT00291096 (https://classic.clinicaltrials.gov/show/NCT00291096)
Magnetic Resonance Imaging of Breast Cancer
NCT ID: NCT01035112 (https://classic.clinicaltrials.gov/show/NCT01035112)
Enhancing Cancer Prevention and Control Pathways-Native Health Initiative
NCT ID: NCT04259762 (https://classic.clinicaltrials.gov/show/NCT04259762)
Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)
NCT ID: NCT04341129 (https://classic.clinicaltrials.gov/show/NCT04341129)
Nipple Aspirate Fluid in Detecting Breast Cancer
NCT ID: NCT03715959 (https://classic.clinicaltrials.gov/show/NCT03715959)
Comparison of Synthetic Mammography Versus Full-Field Digital Mammography in Image Interpretation and Performance Metrics
NCT ID: NCT05056818 (https://classic.clinicaltrials.gov/show/NCT05056818)
African Cancer Genome: GMD
NCT ID: NCT05754658 (https://classic.clinicaltrials.gov/show/NCT05754658)
Early Detection of Breast Cancer in Women With Suspicious Mammograms
NCT ID: NCT03147430 (https://classic.clinicaltrials.gov/show/NCT03147430)
A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer
NCT ID: NCT04086875 (https://classic.clinicaltrials.gov/show/NCT04086875)
Writing Interventions in Breast Cancer Patients Taking Aromatase Inhibitors
NCT ID: NCT04651452 (https://classic.clinicaltrials.gov/show/NCT04651452)
Predicting Chronic Pain Following Breast Surgery
NCT ID: NCT04967352 (https://classic.clinicaltrials.gov/show/NCT04967352)
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
NCT ID: NCT04722692 (https://classic.clinicaltrials.gov/show/NCT04722692)
With Love, Grandma ("Con Cariño, Abuelita") Pilot Study
NCT ID: NCT05721976 (https://classic.clinicaltrials.gov/show/NCT05721976)
The Genomic Medicine at VA Study
NCT ID: NCT04331535 (https://classic.clinicaltrials.gov/show/NCT04331535)
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
NCT ID: NCT04711109 (https://classic.clinicaltrials.gov/show/NCT04711109)
YES Study - Newly Diagnosed/Metastatic Intervention
NCT ID: NCT04379414 (https://classic.clinicaltrials.gov/show/NCT04379414)
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
NCT ID: NCT00579514 (https://classic.clinicaltrials.gov/show/NCT00579514)
Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.
NCT ID: NCT05113927 (https://classic.clinicaltrials.gov/show/NCT05113927)
RANKL Inhibition and Mammographic Breast Density
NCT ID: NCT04067726 (https://classic.clinicaltrials.gov/show/NCT04067726)
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome
NCT ID: NCT04009148 (https://classic.clinicaltrials.gov/show/NCT04009148)
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
NCT ID: NCT03635632 (https://classic.clinicaltrials.gov/show/NCT03635632)
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT ID: NCT04961996 (https://classic.clinicaltrials.gov/show/NCT04961996)
The PROMISE Study: Duavee in Women With DCIS
NCT ID: NCT02694809 (https://classic.clinicaltrials.gov/show/NCT02694809)
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
NCT ID: NCT04496739 (https://classic.clinicaltrials.gov/show/NCT04496739)
Dedicated Breast CT for Quantitative Breast Density Measurements in Mexican-origin Women in Southern Arizona
NCT ID: NCT04799665 (https://classic.clinicaltrials.gov/show/NCT04799665)
Ruxolitinib for Premalignant Breast Disease
NCT ID: NCT02928978 (https://classic.clinicaltrials.gov/show/NCT02928978)
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.